Pharma | Business Upturn

Pharma sector stocks today, Feb 1: Shilpa Medicare rally 8%, Sun Pharma up 3%, Aurobindo Pharma falls 2.21%

Aman Shukla — Sun, 01 Feb 2026 04:37:24 +0000

The Indian pharmaceutical sector showed mixed performance as of February 1, 2026, around 10 AM IST, with many stocks trading in negative territory amid cautious market sentiment ahead of the Union Budget 2026. The broader market indices were volatile, with the Nifty 50 near 25,300-25,320 levels (flat to slightly down) and the Sensex around 82,300 (marginally up or flat in early trade).

The provided data lists BSE and NSE prices with percentage changes for various pharma scrips at approximately 10 AM. Most stocks recorded minor declines, though some showed gains.

Key Observations from the Data (as of ~10 AM IST, Feb 1, 2026):

Top Gainers:
- Shilpa Medicare: +9.73% on BSE (318.15 Rs), +7.63% on NSE (311.00 Rs).
- Suven Life Sciences: +2.33% on BSE (135.90 Rs).
- Indraprastha Medical: +2.11% on BSE (371.00 Rs).
- Sun Pharma: +1.76% on BSE (1,623.10 Rs), +1.86% on NSE (1,625.00 Rs).
- Dishman Carbogen Amcis: +1.63% on BSE (221.75 Rs).
Notable Decliners:
- Jubilant Industries: -4.08% on BSE (1,639.05 Rs).
- Advanced Enzyme Technologies: -3.56% on BSE (286.00 Rs).
- Alivus Life Sciences: -2.76% on BSE (934.90 Rs).
- Aurobindo Pharma: -2.21% on BSE (1,185.50 Rs).
- Several mid- and large-cap names like Glenmark Pharma (-1.67% to -1.85%), Granules India (-1.47%), and IPCA Labs (-1.19% to -1.48%) traded lower.
Major Large-Cap Pharma Stocks:
- Sun Pharma: Up around 1.76-1.86%, supported by recent positive Q3 FY26 results (16% YoY profit growth reported earlier).
- Divi’s Laboratories: Minor dip (-0.20% to -0.05%).
- Cipla: Slight decline (-0.26% to -0.23%).
- Dr. Reddy’s Labs: Nearly flat (-0.04% to -0.02%).
- Torrent Pharma: Minor decline (-0.35% to -0.38%).
- Abbott India: Down -0.88% to -0.51%.
Other Notes:
- Many stocks showed declines of 0.5-2%, reflecting sector caution.
- Some like Alembic (+0.08% to +0.05%), Concord Biotech (+0.60% to +0.43%), and Marksans Pharma (+0.34% to +0.79%) held positive or flat.
- The Nifty Pharma index (from recent references) was around 21,700-21,730 levels earlier in the session, with minor positive bias in some reports, though individual stocks varied.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Pharma sector stocks fall today: Cipla drops 1.52%, Divi’s Laboratories falls 0.78%, Alembic Pharma down 0.52%

Aman Shukla — Mon, 19 Jan 2026 04:58:51 +0000

The Indian pharmaceutical sector experienced a downturn on January 19, 2026, with many listed pharma stocks trading lower in early morning sessions around 10:25 AM IST.

The S&P BSE Healthcare index stood at 42,597.96, reflecting a decline of 0.61%. Broader market benchmarks also traded lower, with the S&P BSE Sensex at 83,030.09 (down 0.65%) and the Nifty 50 at 25,533.15 (down 0.63%).

Key Pharma Stock Movements (as of 10:25 AM)

Most stocks in the sector showed negative price changes on both BSE and NSE:

Aarti Drugs: BSE ₹380.10 (-1.58%), NSE ₹380.20 (-1.32%)
Ajanta Pharma: BSE ₹2,681.35 (+0.04%), NSE ₹2,679.60 (-0.05%)
Alembic Pharma: BSE ₹771.60 (-0.48%), NSE ₹770.90 (-0.52%)
Aurobindo Pharma: BSE ₹1,166.65 (-0.48%), NSE ₹1,169.20 (-0.30%)
Biocon: BSE ₹378.15 (+0.16%), NSE ₹376.65 (-0.26%)
Cipla: BSE ₹1,375.05 (-1.64%), NSE ₹1,376.30 (-1.52%)
Divi’s Laboratories: BSE ₹6,178.90 (-0.88%), NSE ₹6,187.50 (-0.78%)
Dr. Reddy’s Lab: BSE ₹1,172.95 (-0.22%), NSE ₹1,173.40 (-0.18%)
Glenmark Pharma: BSE ₹1,997.10 (-0.17%), NSE ₹1,996.20 (-0.22%)
Indoco Remedies: BSE ₹215.85 (-1.30%), NSE ₹216.69 (-1.15%)
Ipca Labs: BSE ₹1,500.00 (-0.60%), NSE ₹1,500.00 (-0.66%)
J.B. Chemicals: BSE ₹1,903.00 (+0.08%), NSE ₹1,902.40 (-0.08%)
Lupin: BSE ₹2,168.95 (-0.34%), NSE ₹2,168.40 (-0.44%)
Mankind Pharma: BSE ₹2,153.30 (-1.05%), NSE ₹2,148.70 (-1.23%)
Natco Pharma: BSE ₹854.15 (-0.68%), NSE ₹854.45 (-0.58%)
Orchid Pharma: BSE ₹717.70 (-0.79%), NSE ₹715.15 (-1.27%)
Panacea Biotec: BSE ₹398.40 (-1.14%), NSE ₹398.80 (-0.81%)
Strides Pharma Science: BSE ₹883.45 (-1.91%), NSE ₹882.85 (-1.92%)
Sudeep Pharma Ltd.: BSE ₹571.55 (-2.46%), NSE ₹571.45 (-2.56%)
Sun Pharma: BSE ₹1,670.00 (+0.05%), NSE ₹1,672.40 (+0.21%)
Torrent Pharma: BSE ₹4,031.25 (+0.31%), NSE ₹4,034.00 (+0.39%)
Wockhardt: BSE ₹1,415.95 (-0.93%), NSE ₹1,414.00 (-0.95%)
Zydus Lifesciences: BSE ₹864.20 (-0.41%), NSE ₹865.25 (-0.33%)

Notable decliners included Sudeep Pharma Ltd. (down over 2.4%), Strides Pharma Science (down around 1.9%), and Cipla (down over 1.5%). A few stocks, such as Torrent Pharma, Sun Pharma, and Ajanta Pharma (on BSE), showed minor gains or were nearly flat.

Pharma sector stocks today: Natco Pharma jumps 1.24%, Dr. Reddy’s Lab gain 0.32%, Divi’s Laboratories up 0.14%

Aman Shukla — Fri, 09 Jan 2026 05:02:45 +0000

The Indian pharmaceutical sector showed mixed performance on January 9, 2026, amid a slightly declining broader market. As of approximately 10:20 AM IST, the S&P BSE Healthcare Index stood at 43,985.34, down 0.35%. The S&P BSE Sensex was at 84,105.75, down 0.09%, while the Nifty 50 was at 25,862.70, down 0.05%.

Most major pharma stocks traded flat to lower.

Key Pharma Stocks Prices and Changes (as of ~10:20 AM)

Company	NSE Price (₹)	NSE Change (%)
Natco Pharma	921.00	+1.24
Dr. Reddy’s Lab	1,210.80	+0.32
Divi’s Laboratories	6,610.00	+0.14
Strides Pharma Science	969.30	+0.13
Biocon	378.30	+0.09
Cipla	1,460.00	-0.04
Aurobindo Pharma	1,204.20	-0.16
J.B. Chemicals	1,904.80	-0.32
Aarti Drugs	391.35	-0.37
Torrent Pharma	4,008.30	-0.45
Lupin	2,180.00	-0.50
Zydus Lifesciences	902.45	-0.56
IPCA Labs	1,535.00	-0.58
Sun Pharma	1,750.00	-0.61
Ajanta Pharma	2,816.90	-0.76
Glenmark Pharma	2,062.90	-0.81
Alembic Pharma	806.70	-0.99
Wockhardt	1,443.90	-0.99
Orchid Pharma	744.65	-1.64
Mankind Pharma	2,223.90	-1.65
Panacea Biotech	413.40	-4.38

NSE Top Gainers and Losers in Pharma Sector

Top Gainers (NSE):

Natco Pharma: +1.24%
Dr. Reddy’s Laboratories: +0.32%

Top Losers (NSE):

Panacea Biotech: -4.38%
Mankind Pharma: -1.65%
Orchid Pharma: -1.64%

The pharma sector underperformed the broader market slightly on this day, with limited positive movements. Prices are subject to change as trading continues.

Note: Data is based on snapshot as of around 10:20 AM IST on January 9, 2026. Stock markets are volatile, and investors should conduct their own research.

Mankind Pharma IPO to open on April 25

Markets Desk — Thu, 20 Apr 2023 11:55:05 +0000

Mankind Pharma Limited (the “Company”) is set to open its initial public offering of 40,058,844 Equity Shares (“Offer”) on Tuesday, April 25, 2023. The offer will close Thursday, April 27, 2023. The Anchor Investor Bidding Date is one Working Day prior to Bid/Offer Opening Date, that is, April 24, 2023.

The Price Band of the Offer has been fixed from ₹ 1,026 per Equity Share to ₹ 1,080 per Equity Share. Bids can be made for a minimum of 13 Equity Shares and in multiples of 13 Equity Shares thereafter.

The Offer of 40,058,844 Equity Shares comprises an offer for sale of 3,705,443 Equity Shares by Ramesh Juneja; 3,505,149 Equity Shares by Rajeev Juneja; 2,804,119 Equity Shares by Sheetal Arora (collectively, the “Promoter Selling Shareholders”); 17,405,559 Equity Shares by Cairnhill CIPEF Limited; 2,623,863 Equity Shares by Cairnhill CGPE Limited; 9,964,711 Equity Shares by Beige Limited; and 50,000 Equity Shares by Link Investment Trust (collectively, the “Investor Selling Shareholders”, and together with the “Promoter Selling Shareholders”, the “Selling Shareholders”).

Aurobindo Pharma share rises 4% as it maintains outperform call on stock

Shivya Kumar — Mon, 23 Aug 2021 05:30:49 +0000

The global research firm Aurobindo Pharma outperformed on the stock, with a rise of 4 per cent. The company had a target of Rs 830 per share. While Cronus Pharma stopped allay capital allocation between the two, which became the key component in unlocking the rise of the stakes.

Reports claim that on August 20 Pharma Company announced that a deal of Rs 450 crore to conjure 51 per cent stakes in Cronus Pharma speciality were cancelled.

12 August reports state that the company was enacting upon the merger with Hyderabad-based Cronus, a company associated with the production of generic veterinary pharmaceutical products and inclusive of development and manufacturing of these goods.

The firm had compiled on agreements with the Cronus company for 51 per cent partnership 95,059,963 equity shares of Rs 10 each at a premium of Rs 34.18 per equity share evaluating up to Rs 420 crore.

In a regulatory filing on Friday, Aurobindo Pharma said, “The board of directors in its meeting held today has approved the termination of the aforesaid agreements, and the parties have mutually agreed and terminated the said agreements.”

The stock was elevating at Rs 710.60, up to Rs 29.15, or 4.28 per cent at 09:33 hours. It rose to an intraday high of Rs 725.90 and an intraday low of Rs 703.85.

Cipla reports strong growth of 68.5% in domestic sales in June quarter

Sneha Sengupta — Mon, 09 Aug 2021 08:32:20 +0000

Cipla limited established a brilliant performance in the June quarter (Q1FY22). This was followed by a 68.5% growth in domestic sales that comprised almost half of the total sales.

The US region that endows nearly one-fifth of its total revenue witnessed a stable performance. The contribution from respiratory inhaler Albuterol generics continues to render market gains at set rates. The firm accounted for the 5% year-on-year (y-o-y) development in US revenues to the recurring market share of Albuterol.

Cipla’s sales in the geographical landscape of South Africa, Sub-Saharan Africa and Global Access (SAGA) region attributed to 13% y-o-y growth as per USD. This area contributed to nearly 15% of total revenues. The company said that experienced a double-digit growth and market share profit in the Antiretroviral and oncology private market. It also rose to three places to third position in the systemic anti-infectives private market.

Cipla’s total revenue rose over 27% y-o-y to ₹5,453 crore, much higher than the ₹4,606.5 crore in the last quarter. While Ebitda at ₹1,346 crore also accounted for a 28% y-o-y growth, where net profit spiked at 24% y-o-y. Analyst at the Kotak Institutional Equities averred that “Q1FY22 sales and Ebitda exceeded their estimates by 7% and 9%, respectively, led by higher-than-expected domestic sales amid strong traction in the covid portfolio.”

“We expect the covid portfolio to moderate over the near-term, though continued roll-out of the respiratory franchisee in the US and strong execution of One India strategy will help drive earnings growth over FY23-24,” said analysts at Kotak Institutional Equities.

Analysts at Motilal Oswal Financial Services Ltd have increased their EPS percentile scale by 6% and 4% for FY22 and FY23, pertaining to the strong traction in prescription and trade generics coming from the domestic formulations segment with prolonged benefits of cost savings and lower research and development expenditure.

Piramal Enterprise searching acquisition opportunities in multiple pharma asset

Govindraj Muttepawar — Fri, 25 Jun 2021 12:35:35 +0000

Piramal Enterprise Ltd commonly known as PEL has said that they are looking to multiply their acquisition opportunities across the pharma business, including the re entry in domestic formulation, which they had exited back in 2010.

In its FY21 annual reports, the company said that it is looking at acquisition of very niche manufacturing capability for the Contract Development and Manufacturing Organisation (CDMO).

CDMO is a company which serves other businesses and companies specifically in pharmaceutical industry through contract basis which helps them provide with a comprehensive service from drug development to manufacturing processes.

Ajay Piramal, the chairman of Piramal Enterprise Ltd in their annual report said that, “the Carlyle Group’s recent strategies in investment confirms that the business is underlying strength and can provide with war chest for the upcoming phases on the company growth.”

Piramal added that each of the pharma businesses always have a compelling planning for their organic growth including multiple acquisition opportunities. They believe to continue to deliver in this line with a long term growth record through sustainable initiatives.

Last year Piramal had raised 3,523 cr from Carlyle in one of the largest PE deals in the Indian pharmaceutical sector. This deal was structured in a manner that the pharma business was clubbed with a subsidiary enterprise under the company itself. In this deal 20 per cent equity wad given to Carlyle.

Almost 63 per cent of the revenues of the whole pharma businesses come from CDMO business, under which the company typically provides with manufacturing services and development for generic companies and also innovators.

Pharma index rises to 5-year-high at Rs 12,636

Akanksha Yadav — Mon, 07 Dec 2020 08:17:14 +0000

Pharma in a bullish market trade at the National Stock Exchange rose to a 5-year-high of Rs 12,636.90 on Monday. The market opened on a good note for pharma as its price rallied almost doubled at Rs 12,636.90 as against Rs 6242.85 during the year-ago period. It recorded an intraday high of Rs 12, 636.90 whereas an intraday low of Rs 12,314.80. The market had opened at Rs 12,376.45.

Pharma trades during the September quarter of the fiscal year have been very impressive, all thanks to the rampant increase in the demand for medical products as the COVID-19 pandemic hit the globe. There has been a drastic increase in the demand and supply of PPE kits, masks, oxygen cylinders and other equipment.

The recent development in the COVID-19 vaccine candidates being developed by Serum Institute of India and its application for the authorisation of emergency use in India has given a strong push to the pharma industry’s trade. The other vaccine contenders being developed across India are also proving crucial in raising the market trend.

According to the US-based Duke University Global Health Innovation Center, India has purchased 500 million doses of the Oxford University-AstraZeneca vaccine candidate, one billion from the US company Novavax and 100 million doses of the Sputnik V candidate from Russia’s Gamaleya Research Institute. India has ordered a sum total of 1.6 billion vaccines for its people.

With expected further developments in the pharma fields, the market is expected to perform well in the coming months.